Nickel J Curtis, Parsons C Lowell, Forrest John, Kaufman David, Evans Robert, Chen Andrew, Wan George, Xiao Xiaoying
Queen's University-Urology, Kingston, Ontario, Canada.
J Sex Med. 2008 Feb;5(2):394-9. doi: 10.1111/j.1743-6109.2007.00686.x. Epub 2007 Dec 14.
Sexual functioning is one of the strongest predictors of poorer quality of life (QOL) in patients diagnosed with interstitial cystitis/painful bladder syndrome (IC/PBS).
To examine the relationship between symptom reduction and sexual functioning in patients with IC/PBS.
Patients with IC/PBS were treated with 300 mg/day pentosan polysulfate sodium for 32 weeks.
Patients completed the O'Leary-Sant Interstitial Cystitis Symptom Index, Short Form-12 QOL, and Medical Outcomes Study Sexual Functioning Scale at baseline, and at 8, 16, 24, and 32 weeks. Treatment responders were defined as those achieving a >/=30% reduction in symptom index from baseline.
A total of 128 patients were included in the analyses. At baseline, mean symptom index, QOL (physical and mental), and sexual functioning scores were 12.3, 41.7, 45.9, and 56.1, respectively. Patients showed statistically significant improvement in symptom and sexual functioning scores at weeks 8, 16, 24, and 32. At week 32, the mean change in symptom index score from baseline was -2.97 (standard deviation [SD] = 4.66, P < 0.0001), and the mean change in sexual functioning score from baseline was 8.9 (SD = 32.9, P = 0.0054). Reduction in symptom index score was moderately correlated with improvement in sexual functioning score at the end of study (r = -35, P = 0.0002). Positive correlation was observed at the end of the study between the mean change scores of sexual functioning score and physical and mental QOL components (r = 0.46, P < 0.0001 and r = 0.29, P = 0.0023, respectively). Patients achieving a >/=30% reduction in symptom index (responder, N = 47; 44%) had an adjusted mean change in sexual functioning score of 19.8 (standard error [SE] = 4.69), while nonresponders (N = 59, 56%) had an adjusted mean change -0.49 (SE = 4.17) (between groups, P = 0.0020).
Sexual dysfunction is moderate to severe in patients with IC/PBS and impacts significantly on QOL. Reduction in symptoms was associated with improvement in the patient-reported outcomes of sexual function.
性功能是诊断为间质性膀胱炎/膀胱疼痛综合征（IC/PBS）患者生活质量较差的最强预测因素之一。
研究IC/PBS患者症状减轻与性功能之间的关系。
IC/PBS患者接受300毫克/天的聚磺基琥珀酸钠治疗32周。
患者在基线时以及第8、16、24和32周时完成奥利里-桑特间质性膀胱炎症状指数、简明健康调查12项生活质量量表和医学结局研究性功能量表。治疗反应者定义为症状指数较基线降低≥30%的患者。
共有128名患者纳入分析。基线时，平均症状指数、生活质量（身体和心理）以及性功能得分分别为12.3、41.7、45.9和56.1。患者在第8、16、24和32周时症状和性功能得分有统计学意义的改善。在第32周时，症状指数得分较基线的平均变化为-2.97（标准差[SD]=4.66，P<0.0001），性功能得分较基线的平均变化为8.9（SD=32.9，P=0.0054）。研究结束时症状指数得分的降低与性功能得分的改善呈中度相关（r=-0.35，P=0.0002）。研究结束时观察到性功能得分的平均变化得分与身体和心理生活质量成分之间呈正相关（分别为r=0.46，P<0.0001和r=0.29，P=0.0023）。症状指数降低≥30%的患者（反应者，N=47；44%）性功能得分的调整后平均变化为19.8（标准误[SE]=4.69），而无反应者（N=59，56%）的调整后平均变化为-0.49（SE=4.17）（组间比较，P=0.0020）。
IC/PBS患者存在中度至重度性功能障碍，对生活质量有显著影响。症状减轻与患者报告性功能结局的改善相关。
